Curiosis, a laboratory automation (lab automation) equipment specialist seeking to list on the KOSDAQ market, secured more than 7 trillion won in deposits from retail subscriptions.
On the 5th, Curiosis said that from the 4th through the day it conducted an initial public offering subscription for retail investors, drawing orders for more than 660 million shares for 300,000 shares on offer.
Subscription deposits totaled 7.27 trillion won, and the overall subscription competition rate was 2,203.97 to 1.
Curiosis, a lab automation equipment company specializing in the development and manufacture of imaging and separation equipment for drug development and cell therapy production, started in 2015.
Its flagship products are the live-cell imaging system "Celloger" and the cell separation device "Cellfury." Last year, on a consolidation basis, it posted 5.4 billion won in revenue and an operating loss of 6.2 billion won. The company set a goal of turning to an operating profit next year.
Earlier, the company drew strong demand in a book-building for institutional investors. It secured orders at or above the top end of the indicative price range from 99.9% of participating institutions and set the offering price at 22,000 won.
The company plans to use the IPO proceeds to expand production facilities at its factory in Yongin, Gyeonggi Province. It also plans to hire additional staff, aiming to achieve revenue in the 47 billion won range by 2028.
Yun Ho-young, CEO of Curiosis, said, "We will grow into the world's best lab automation total solution provider that can meet investors' expectations."
Meanwhile, Curiosis set the 13th as its KOSDAQ market listing date. The underwriter is Kiwoom Securities.